Cargando…

Medication adversely impacts visually-guided eye movements in Parkinson’s disease

OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirt...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Miranda J., Reilly, James L., Pal, Gian D., Metman, Leo Verhagen, Rivera, Yessenia M., Drane, Quentin H., Corcos, Daniel M., David, Fabian J., Goelz, Lisa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193957/
https://www.ncbi.nlm.nih.gov/pubmed/35995722
http://dx.doi.org/10.1016/j.clinph.2022.07.505
_version_ 1785043920129884160
author Munoz, Miranda J.
Reilly, James L.
Pal, Gian D.
Metman, Leo Verhagen
Rivera, Yessenia M.
Drane, Quentin H.
Corcos, Daniel M.
David, Fabian J.
Goelz, Lisa C.
author_facet Munoz, Miranda J.
Reilly, James L.
Pal, Gian D.
Metman, Leo Verhagen
Rivera, Yessenia M.
Drane, Quentin H.
Corcos, Daniel M.
David, Fabian J.
Goelz, Lisa C.
author_sort Munoz, Miranda J.
collection PubMed
description OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirty-three participants with Parkinson’s disease (PD) completed the VGS tasks OFF and ON medication, along with 13 healthy controls. Performance on 3 paradigms (gap, step, and overlap) and 2 target eccentricities was recorded. We used mixed models to determine the effect of medication, paradigm, and target eccentricity on saccade latency, gain, and peak velocity. RESULTS: First, we confirmed known paradigm effects on latency, and target eccentricity effects on gain and peak velocity in participants with PD. Second, latency was positively associated with OFF medication Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score in PD. Third, medication prolonged latency for the larger target eccentricity across the 3 paradigms, while decreasing gain and peak velocity in the step paradigm across target eccentricities. CONCLUSIONS: Medication adversely affected and was not therapeutically beneficial for VGS. Previous inconsistencies may have resulted from chosen target eccentricity. SIGNIFICANCE: The negative medication effect on VGS may be clinically significant, as many activities in daily life require oculomotor control, inhibitory control, and visually-guided shifts of attention.
format Online
Article
Text
id pubmed-10193957
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-101939572023-05-18 Medication adversely impacts visually-guided eye movements in Parkinson’s disease Munoz, Miranda J. Reilly, James L. Pal, Gian D. Metman, Leo Verhagen Rivera, Yessenia M. Drane, Quentin H. Corcos, Daniel M. David, Fabian J. Goelz, Lisa C. Clin Neurophysiol Article OBJECTIVE: We examined whether previous inconsistent findings about the effect of anti-Parkinsonian medication on visually-guided saccades (VGS) were due to the use of different paradigms, which change the timing of fixation offset and target onset, or different target eccentricities. METHODS: Thirty-three participants with Parkinson’s disease (PD) completed the VGS tasks OFF and ON medication, along with 13 healthy controls. Performance on 3 paradigms (gap, step, and overlap) and 2 target eccentricities was recorded. We used mixed models to determine the effect of medication, paradigm, and target eccentricity on saccade latency, gain, and peak velocity. RESULTS: First, we confirmed known paradigm effects on latency, and target eccentricity effects on gain and peak velocity in participants with PD. Second, latency was positively associated with OFF medication Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score in PD. Third, medication prolonged latency for the larger target eccentricity across the 3 paradigms, while decreasing gain and peak velocity in the step paradigm across target eccentricities. CONCLUSIONS: Medication adversely affected and was not therapeutically beneficial for VGS. Previous inconsistencies may have resulted from chosen target eccentricity. SIGNIFICANCE: The negative medication effect on VGS may be clinically significant, as many activities in daily life require oculomotor control, inhibitory control, and visually-guided shifts of attention. 2022-11 2022-08-08 /pmc/articles/PMC10193957/ /pubmed/35995722 http://dx.doi.org/10.1016/j.clinph.2022.07.505 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Munoz, Miranda J.
Reilly, James L.
Pal, Gian D.
Metman, Leo Verhagen
Rivera, Yessenia M.
Drane, Quentin H.
Corcos, Daniel M.
David, Fabian J.
Goelz, Lisa C.
Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title_full Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title_fullStr Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title_full_unstemmed Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title_short Medication adversely impacts visually-guided eye movements in Parkinson’s disease
title_sort medication adversely impacts visually-guided eye movements in parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193957/
https://www.ncbi.nlm.nih.gov/pubmed/35995722
http://dx.doi.org/10.1016/j.clinph.2022.07.505
work_keys_str_mv AT munozmirandaj medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT reillyjamesl medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT palgiand medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT metmanleoverhagen medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT riverayesseniam medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT dranequentinh medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT corcosdanielm medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT davidfabianj medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease
AT goelzlisac medicationadverselyimpactsvisuallyguidedeyemovementsinparkinsonsdisease